ICOS and non-small cell lung carcinoma: In patients with non-small cell lung cancer (NSCLC), the combined baseline levels of circulating classical monocytes, NK cells and ICOS+ CD4+ T cells were found to correlate with response to the anti-PD-1 ICPi pembrolizumab [65], resulting in the creation of a de-multiplexed, immune peripheral score based on those three cell types, which could be easily implemented in the clinical routine for stratifying patients to ICPi therapy.